<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139680">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02071082</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-292-1249</org_study_id>
    <nct_id>NCT02071082</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults</brief_title>
  <official_title>A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy, safety, and tolerability of a single table regimen
      (STR) containing elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in
      human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infected adults through 48
      weeks.

      Participants will be enrolled into two cohorts:

        -  Cohort 1: HIV treatment-naive and HBV treatment-naive

        -  Cohort 2: HIV-suppressed
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants with plasma HBV DNA levels &lt; 29 copies/mL</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with plasma HIV-1 RNA level &lt; 50 copies/mL per the FDA snapshot definition</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with plasma HBV DNA levels &lt; 29 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with plasma HIV-1 RNA level &lt; 50 copies/mL per FDA snapshot definition</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with normalized alanine aminotransferase (ALT)</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with seroconversion</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FibroTest® score</measure>
    <time_frame>Baseline to Weeks 24 and 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV</condition>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>HIV treatment-naive and HBV treatment-naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV treatment-naive and HBV treatment-naive participants will receive E/C/F/TAF for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-suppressed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV/HBV co-infected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E/C/F/TAF</intervention_name>
    <description>Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg (E/C/F/TAF) STR administered orally once daily with food</description>
    <arm_group_label>HIV treatment-naive and HBV treatment-naive</arm_group_label>
    <arm_group_label>HIV-suppressed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both Cohorts 1 and 2:

               -  The ability to understand and sign a written informed consent form, which must
                  be obtained prior to initiation of study procedures

               -  HIV/HBV co-infected adult males and non-pregnant and non-lactating females

               -  No evidence of hepatocellular carcinoma (HCC) or clinical or imaging evidence of
                  cirrhosis (ascites, variceal bleeding, encephalopathy).

                  --- Subjects should have documentation of an abdominal ultrasound in the 12
                  months prior to screening, or an abdominal ultrasound at screening,
                  demonstrating the absence of cirrhosis and HCC.

               -  Acute Hepatitis A virus (HAV) immunoglobulin M (IgM) negative

               -  Hepatitis C virus (HCV) Ab negative, or HCV Ab positive with negative HCV RNA

               -  Hepatitis D virus (HDV) Ab negative, or HDV Ab positive with negative HDV RNA

               -  Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the
                  Cockcroft-Gault formula

               -  CD4+ count of &gt; 200 cells/μL

               -  Chronic HBV infection as defined by HBsAg positive for ≥ 6 months (may be HBeAg
                  positive or negative), or HBsAg and HBcAb (by 200-fold dilution) positive at
                  screening, or other laboratory evidence of chronic HBV infection for ≥ 6 months,
                  such as positive HBV DNA

          -  Cohort 1 (HIV and HBV treatment naive) only:

               -  No current or prior anti-HIV treatment, including antiretroviral medications
                  received for prevention (PrEP), or post exposure prophylaxis (PEP)

               -  No current or prior anti-HBV treatment

               -  Plasma HIV-1 RNA level ≥ 500 copies/mL at screening

               -  Screening HBV DNA ≥ 3 log10 IU/mL and &lt; 9 log10 IU/mL

          -  Cohort 2 (HIV suppressed) only:

               -  Receiving current antiretroviral regimen for at least 4 consecutive months

               -  No current or prior regimen containing 3 active anti-HBV agents (i.e. cannot be
                  on TDF/FTC/Entecavir or TDF/3TC/Entecavir)

               -  Maintained plasma HIV-1 RNA &lt; 50 copies/mL for 6 consecutive months prior to and
                  at the time of the screening visit. Unconfirmed virologic evaluation of ≥ 50
                  copies/mL after previously reaching viral suppression (transient detectable
                  viremia, or &quot;blip&quot;) and prior to screening is acceptable

               -  Documented positive HIV antibody test

               -  Screening HBV DNA &lt; 9 log10 IU/mL

        Exclusion Criteria:

          -  Females who are breastfeeding

          -  Positive serum pregnancy test (female of childbearing potential)

          -  Have an implanted defibrillator or pacemaker

          -  Current alcohol or substance use

          -  A history of malignancy within the past 5 years (prior to screening) or ongoing
             malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or
             resected, non-invasive carcinoma.

          -  Received solid organ or bone marrow transplant

          -  Any history of, or current evidence of, clinical hepatic decompensation (e.g.,
             ascites, encephalopathy or variceal hemorrhage).

          -  Significant bone disease (e.g., osteomalacia, chronic osteomyelitis, osteogenesis
             imperfecta, osteochondroses), or multiple bone fractures

          -  Active, serious infections (other than HIV-1 infection) requiring parenteral
             antibiotic or antifungal therapy within 30 days prior to Day 1

          -  Subjects on hemodialysis, other forms of renal replacement therapy, or on treatment
             for underlying kidney diseases (including prednisolone, and dexamethasone)

          -  Any other clinical condition or prior therapy that, in the opinion of the
             Investigator, would make the subject unsuitable for the study or unable to comply
             with the dosing requirements

          -  Investigational agents (unless approved by Gilead Sciences). Participation in any
             other clinical trial without prior approval from the sponsor is prohibited while
             participating in this trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moupali Das, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Lopez</last_name>
    <phone>650-372-4456</phone>
    <email>marc.lopez@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Spectrum Medical Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-604-9500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF Research Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-913-1033</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter J. Ruane MD, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>323-954-0400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anthony Mills MD, Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-550-2271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-783-3737</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95811</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>916-914-6319</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whitman Walker Health</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-797-3500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>GWU Medical Faculty Associates</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>202-741-2443</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barry M. Rodwick MD</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>727-216-6193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gary J Richmond M.D.,P.A.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-524-2250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>772-464-9746</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>786-413-7546</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AHF-Kinder Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>786-497-4000</phone>
      <phone_ext>232</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>AIDS Health Foundation/WPA</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-538-1400</phone>
      <phone_ext>2520</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-647-3960</phone>
      <phone_ext>2112</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>SJH Comprehensive Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>813-870-4760</phone>
      <phone_ext>230</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>AIDS Research and Treatment Center of the Treasure Coast</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>772-978-9556</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-855-7871</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>404-686-5198</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercer University</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>478-301-5846</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>773-388-8792</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-695-5090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center PC</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>248-544-9300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>313-916-1784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KC Care Clinic</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>816-777-2757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central West Clinical Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>314-652-0100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton Healthcare, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-647-2200</phone>
      <phone_ext>116</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>973-877-2735</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest CARE Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>505-216-0318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>518-262-6323</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>252-744-1913</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rosedale Infectious Diseases</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>704-948-8582</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-480-9660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Hope Foundation, Inc.</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-844-8035</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Diseases Consultants</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-276-5618</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Garcias' Family Health Group</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>956-421-4935</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gordon E. Crofoot MD PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-526-0005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TheUniversity of Texas Health Science Center Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-500-6703</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cure C Consortium</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-526-9821</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter Shalit MD</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>206-624-1441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>613-737-8209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network/Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>416-340-4800</phone>
      <phone_ext>6723</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maple Leaf Research/Maple Leaf Medical Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>4164657936</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of the MUHC-Montreal Chest Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>514-934-1934</phone>
      <phone_ext>32537</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HBV</keyword>
  <keyword>Coinfection</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
